372.3 ð¥ å §ç§å°ç§èåç
372.3.1 Mechanistic Deep Dive
372.3.1.1 Channels + Receptors
Sodium: phenytoin, carbamazepine, oxcarbazepine, lacosamide, lamotrigine Calcium (T-type): ethosuximide, valproate (partial) GABA enhancement: benzodiazepines, barbiturates, vigabatrin, tiagabine Glutamate: perampanel (AMPA), topiramate, felbamate SV2A vesicle: levetiracetam, brivaracetam Mixed: valproate, topiramate, zonisamide
372.3.2 Recent Trials & Updates
372.3.2.1 Cenobamate (Xcopri)
- FDA 2019
- Very high response rate in refractory focal
- DRESS risk (slow titration mandatory)
372.3.2.2 Fenfluramine (Fintepla)
- FDA 2020 Dravet, 2022 LGS
- Serotonin release
- Effective for drop attacks (LGS)
- Cardiac monitoring
372.3.2.6 Anti-Inflammatory Approaches
- Targeted for autoimmune epilepsies
- NORSE/FIRES (febrile infection-related epilepsy syndrome)
- Immunotherapy + ketogenic + anakinra
372.3.3 High-Yield Specialist Points
372.3.3.1 Mesial Temporal Sclerosis
- Most common pathology in epilepsy surgery
- Hippocampal sclerosis on MRI
- History of febrile seizures often
- Excellent surgical outcomes (70%+ seizure free)
372.3.3.2 Cortical Dysplasia
- Common in pediatric epilepsy surgery
- Various types (Type I, II, III)
- FCD type IIb associated with TS
372.3.3.3 Tuberous Sclerosis Complex (TSC)
- TSC1, TSC2
- Cortical tubers
- Subependymal nodules + giant cell astrocytomas
- Epilepsy common (often refractory)
- Everolimus (mTOR inhibitor) â FDA approved for SEGA + refractory epilepsy in TSC
- Vigabatrin first-line for TSC-related infantile spasms
372.3.3.4 Dravet Syndrome
- SCN1A mutation
- Refractory infantile-onset
- Avoid sodium channel blockers (worsen)
- Valproate + clobazam first-line
- Stiripentol, cannabidiol, fenfluramine
372.3.3.5 Lennox-Gastaut Syndrome
- Multiple seizure types (atonic, tonic, atypical absence)
- Slow spike-wave on EEG
- Cognitive impairment
- Drug-resistant
- Valproate, lamotrigine, clobazam, rufinamide, cannabidiol, fenfluramine, vagus nerve stim
- Corpus callosotomy for drop attacks
372.3.3.6 Genetic Epilepsies
- Sodium channelopathies (SCN1A â Dravet, SCN8A)
- Potassium channelopathies (KCNQ2)
- Glutamate receptor (GRIN2A, GRIN2B)
- Synapse-related (STXBP1, SYNGAP1)
- Pyridoxine-dependent (ALDH7A1) â try B6 in neonatal
- Glucose transporter (SLC2A1) â DEET-1; ketogenic diet
372.3.3.7 Autoimmune Epilepsy
- Anti-NMDA-R (psychiatric + seizures + movement)
- Anti-LGI1 (faciobrachial dystonic seizures pathognomonic!)
- Anti-CASPR2
- Anti-GAD65
- Anti-Ma2 (paraneoplastic)
- Immunotherapy + ASMs
372.3.3.8 Faciobrachial Dystonic Seizures
- Pathognomonic of anti-LGI1
- Brief unilateral facial + arm dystonia
- Many per day
- Detect early â immunotherapy â prevent encephalitis
372.3.3.9 Photosensitive Seizures
- JME often
- Stroboscopic stimulation triggers
- Avoid TV close, video games (some)
- ASMs as for syndrome
372.3.4 Pearls
- Seizure â epilepsy (provoked vs unprovoked)
- Witnessed account critical for history
- ILAE 2017: onset (focal vs generalized) + awareness + motor vs non-motor
- ASM by type â choose appropriately
- Pregnancy: lamotrigine + levetiracetam safest
- **HLA-B*1502** screen for CBZ in Asians
- Refractory: 2 ASM failure â surgery/VNS/RNS/DBS/diet/cannabidiol
- Mesial temporal sclerosis: excellent surgical outcome
- Cenobamate (2019) high response in refractory focal
- Cannabidiol for Dravet, LGS, TSC
- Fenfluramine for Dravet, LGS
- Anti-LGI1 + faciobrachial dystonic seizures â autoimmune, immunotherapy
- SUDEP counsel patients